B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Conditions
Brief summary
This laboratory study is looking into genes in samples from younger patients with relapsed acute lymphoblastic leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
Detailed description
OBJECTIVES: I. To identify global changes in the epigenome and various underlying histone modifications that characterize relapsed acute lymphoblastic leukemia (ALL). II. To identify specific transcription factor-binding sites associated with histone alterations. III. To correlate gene expression changes of differentially regulated genes at relapse with underlying chromatin modifications. OUTLINE: Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
Interventions
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of B-cell acute lymphoblastic leukemia * Paired diagnosis-relapse primary patient samples obtained from the Children's Oncology Group (COG) cell bank
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cellular origins of relapse and the underlying epigenetic mechanisms associated with drug resistance | 1 month |
| Genes associated with histone modification | 1 month |
| Biological pathways involved in relapse | 1 month |
Countries
United States
Outcome results
None listed